Application of Array Comparative Genomic Hybridization in Chronic Myeloid Leukemia
Chromosomal alteration is one of the hallmarks of chronic myeloid leukemia (CML), and the Philadelphia chromosome is the most important and key example of the chromosomal changes in this disease. Indeed, the BCR–ABL1 fusion product is a target against which many tyrosine kinase inhibitors (TKIs) have been proven to be effective in the treatment of CML. However, the reality is that CML patients show resistance to TKIs both in an acquired and de novo manner, and the mechanism of TKI resistance is still largely unknown. This phenomenon suggests that in addition to the BCR–ABL mutation, further genetic alterations ...
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news
Targeted cancer treatment case study: 'I'm so grateful that I can live a normal life'
Mary Bacon, 66, from Cumbria, was diagnosed with chronic myeloid leukaemia (CML) in 2008. But targeted treatments mean she can now live a normal life. (Source: The Independent - Science)
Source: The Independent - Science - January 28, 2013 Category: Science Tags: Science Source Type: news
National Academy of Sciences Paper: Dartmouth researchers take novel approach to fighting treatment-resistant chronic myeloid leukemia
In a paper published in the Proceedings of the National Academy of Sciences, researchers at Dartmouth's Geisel School of Medicine described a novel approach to killing chronic myeloid leukemia (CML) cells without harming normal cells, an approach that could help fight off the disease in patients who have developed resistance to standard treatment. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - January 22, 2013 Category: Hospital Management Authors: derik.hertel at dartmouth.edu (Derik Hertel) Source Type: news
Novel Cancer Stem Cell-Targeting Drug Has Potential To Combat Hard-To-Reach Leukemia Stem Cells Responsible For Relapses
Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive - and thus vulnerable - to a novel cancer stem cell-targeting drug currently under development. The findings, published in Cell Stem Cell, open the possibility that diseases like chronic myeloid leukemia (CML) and some solid tumor cancers might - in combination with other therapies - be more effectively treated with this drug, and with a lower chance of relapse... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 21, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Generic imatinib (Imatinib Teva) approved in the EU
Source: European Medicines Agency
Area: News
A generic imatinib product (Imatinib Teva) has been approved in the EU for the treatment of:
. Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
. Paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
. Adult patients with Ph+ CML in blast crisis.
Imatinib Teva is a generic of Glivec®, which has bee...
Source: NeLM - News - January 21, 2013 Category: Drugs & Pharmacology Source Type: news
CHMP recommends approval of bosutinib (Bosulif®) for CML
Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a conditional marketing authorisation for the orphan medicine bosutinib (Bosulif®) for the treatment of adults with Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. Bosutinib is a protein kinase inhibitor that acts by inhibiting the abnormal Bcr-Abl kinase that promotes CML.
The positive...
Source: NeLM - News - January 21, 2013 Category: Drugs & Pharmacology Source Type: news
Study: Enzyme Plays Important Role in CML Stem Cell Reprogramming
Researchers have identified an enzyme that plays an important role in the reprogramming of malignant progenitor cells in chronic myeloid leukemia. The enzyme, ADAR1, could represent a target for selecting and eradicating leukemia stem cells. (Source: Cancer Network)
Source: Cancer Network - January 19, 2013 Category: Cancer & Oncology Source Type: news
Bosutinib in CML Cleared for Approval in EuropeBosutinib in CML Cleared for Approval in Europe
Bosutinib has been recommended for approval in Europe for the treatment of chronic myelogenous leukemia (CML). Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 18, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Therapy Resistance Mechanisms in Myeloid LeukemiaTherapy Resistance Mechanisms in Myeloid Leukemia
The proteomic analysis of bone marrow plasma in chronic myeloid leukemia illustrates how powerful proteomics may be in the discovery of new therapeutics targeting resistance mechanisms. Expert Review of Proteomics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
New Chronic Myelogenous Leukemia Guidelines for Patients Available from NCCN
NCCN has released the NCCN Patient Guidelines for Chronic Myelogenous Leukemia, available free of charge on NCCN.com. NCCN Patient Guidelines are a tool to help patients and their caregivers take a more active role in treatment decisions.
FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®), with the support of the NCCN Foundation, recently announced the latest addition to the library of NCCN Guidelines for Patients™, the NCCN Patient Guidelines™ for Chronic Myelo... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - June 8, 2011 Category: Cancer & Oncology Source Type: news
Second-Line TKIs Offer Expanded Treatment Options for Newly Diagnosed Patients with CML
New first-line therapies for patients with CML highlight notable updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for CML at the National Comprehensive Cancer Network® (NCCN®) 16th Annual Conference.
HOLLYWOOD, FL - Second generation tyrosine kinase inhibitor (TKI) therapies approved for first-line therapy of chronic myelogenous leukemia (CML) offer newly diagnosed patients an expanded range of treatment options, according to Susan O'Brien, MD, of The Universi... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - March 11, 2011 Category: Cancer & Oncology Source Type: news
NCCN Updates Chronic Myelogenous Leukemia Guidelines
Significant new treatment added JENKINTOWN, Pa., October 3, 2006 — The National Comprehensive Cancer Network (NCCN) is proud to announce several new updates to the NCCN Clinical Practice Guidelines in Oncology TM for Chronic Myelogenous Leukemia (CML). These changes highlight leading developments in the treatment of CML and represent the recognized standard for clinical policy in oncology in both the community and the academic practice settings. A panel of world-renowned experts added Dasatinib ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - October 3, 2006 Category: Cancer & Oncology Source Type: news
NCCN Releases Acute Myeloid Leukemia and Chronic Myelogenous Leukemia Chapters of the NCCN DrugsandBiologics Compendium
JENKINTOWN, PA — The National Comprehensive Cancer Network (NCCN) announces the release of Chapters 4 and 5 of the NCCN DrugsandBiologics Compendium: Acute Myeloid Leukemia and Chronic Myelogenous Leukemia.
“The NCCN DrugsandBiologics Compendium contains authoritative and definitive information about the appropriate use of drugs and biologics in the care of patients with leukemia – information that decision-makers at insurance and managed care companies and pharmacy benefits managers can use t... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 28, 2005 Category: Cancer & Oncology Source Type: news
